Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2365 • ACR Convergence 2025
Sustained Efficacy up to 3 Years with Bimekizumab Treatment Across GRAPPA Core Domains in Patients with Psoriatic Arthritis: Long-Term Results from Two Phase 3 Trials
Joseph F Merola¹, Laura Coates², Atul Deodhar³, Alice B. Gottlieb⁴, Enrique R. Soriano⁵, Barbara Ink⁶, Rajan Bajracharya⁶, Jason Coarse⁷ and Philip J. Mease⁸, ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ³Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁴Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁵Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶UCB, Slough, England, United Kingdom, ⁷UCB, Morrisville, NC, ⁸Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A, has demonstrated sustained efficacy to 3 years (yrs) in…
Abstract Number: 2327 • ACR Convergence 2025
Persistent Pain in PsA: A Distinct Phenotype of Depression, Fatigue, And Catastrophizing
Rebecca Haberman¹, Kyra Chen², Adamary Felipe³, Stephanie Eichman³, Uma Scher⁴ and Jose Scher⁵, ¹NYU Langone Health, New York, NY, ²NYU Grossman School of Medicine and NYU Langone Health Psoriatic Arthritis Center, New York, ³NYU Grossman School of Medicine, New York, ⁴NYU School of Medicine, Scarsdale, NY, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Targeted synthetic and biologic DMARDs have transformed psoriatic arthritis (PsA) treatment. Still, a substantial subset of patients reports persistent joint pain despite well-controlled inflammation.…
Abstract Number: 1963 • ACR Convergence 2025
Efficacy of Apremilast in Patients With Psoriatic Arthritis and Pre-existing Dactylitis: Dynamic Contrast-Enhanced MRI Results From the Phase 4 MOSAIC Study
mikael Boesen¹, Philip J. Mease², Walter P Maksymowych³, Robert G. W. Lambert⁴, Olga Kubassova⁵, John Carrino⁶, Kamyar Moradi⁷, Michael R. Bubb⁸, Guillermo Valenzuela⁹, Kurt de Vlam¹⁰, Jyotsna Reddy¹¹, Siddharth Chaudhari¹¹, Zhenwei Zhou¹¹ and Mikkel Ostergaard¹², ¹Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁴University of Alberta, Department of Radiology & Diagnostic Imaging, Edmonton, AB, Canada, ⁵Image Analysis Group, Philadelphia, PA, ⁶Department of Radiology and Imaging, Hospital for Special Surgery, New York, NY, ⁷Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸University of Florida, Gainesville, FL, ⁹Integral Rheumatology & Immunology Specialists, Plantation, FL, ¹⁰Department of Rheumatology, UZ Leuven, Leuven, Belgium, ¹¹Amgen Inc., Thousand Oaks, CA, ¹²Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Primary results from the phase 4 MOSAIC trial demonstrated that apremilast (APR) improved inflammation in patients (pts) with PsA based on PsA MRI scoring…
Abstract Number: 1463 • ACR Convergence 2025
Effective Prevention of Psoriatic Arthritis with Secukinumab: A 5-Year Observation from the SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Weibin Bao⁹ and Karl Gaffney¹⁰, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁰Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Secukinumab, an IL-17A inhibitor, has well-established effectiveness in the treatment of psoriasis (PsO) and psoriatic arthritis (PsA) in both long-term clinical trials and the…
Abstract Number: 1436 • ACR Convergence 2025
Angiogenesis Markers in Difficult to Treat Psoriatic Arthritis Patients
Devy Zisman¹, Amir Haddad², Dunia Araide³, Noa Hayat², Tal Gazitt⁴, Joy Feld⁵, Michal Aizenberg Peleg¹, Muhanad Abu-Elhija¹, Ameen Batheesh¹, Abdulla Watad⁶, Alina Simanovich¹, Nili Stein¹, Kateryna Milman² and Michal Amit Rahat¹, ¹Carmel Medical Center, Haifa, Israel, ²Carmel Medical Centre, Haifa, Israel, ³The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, HaZafon, Israel, ⁴Carmel Hospital, Haifa, Israel, ⁵Carmel and Zvulun Medical Centre, Haifa, Israel, ⁶Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: Difficult to treat (D2T) psoriatic arthritis (PsA) presents a state of active inflammatory disease manifestations despite therapy with at least two biologic disease modifying…
Abstract Number: 1183 • ACR Convergence 2025
Risk of Inflammatory Bowel Disease in Psoriatic Arthritis Patients Treated with IL-17 Inhibitors
Rusudan Tskitishvili¹, Abdallah Hussein², Irakli Tskhakaia³, Nanuka Tsibadze³, Eric Osgood² and Humaira Khan⁴, ¹Virtua Health, Camden, NJ, ²Virtua Health, Camden, ³Jefferson Health - Einstein, Philadelphia, PA, ⁴Virtua Health, Voorhees
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, progressive inflammatory arthritis that significantly impairs quality of life and contributes to substantial morbidity. Interleukin-17 (IL-17) plays a…
Abstract Number: 0573 • ACR Convergence 2025
Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Joseph F Merola¹, Alexis Ogdie², Alice B. Gottlieb³, Fabian Proft⁴, Nuala Brennan⁵, Alex Godwood⁵, Matthew R. Thomas⁵, Eva Cullen⁵, Kristian Reich⁶, Laura Coates⁷ and Laure Gossec⁸, ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁴Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵MoonLake Immunotherapeutics AG, Zug, Switzerland, ⁶MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ⁷Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁸Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Sonelokimab (SLK) is a novel IL-17A- and IL-17F-inhibiting Nanobody designed to target difficult-to-reach sites of inflammation due to its small size and albumin-binding domain.…
Abstract Number: 0873 • ACR Convergence 2025
Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis
Lihi Eder¹, Shangzhong Li², Philip J. Mease³, Christopher Ritchlin⁴, Walter P Maksymowych⁵, Hendrik Schulze-Koops⁶, Josef Smolen⁷, Oliver FitzGerald⁸, Vinod Chandran⁹, Chun Wu¹⁰ and Jinqi Liu², ¹University of Toronto, Toronto, ON, Canada, ²Bristol Myers Squibb, Princeton, NJ, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Rochester Medical Center, Canandaigua, NY, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, ⁷Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁸UCD, Dublin ⁶, Dublin, Ireland, ⁹Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, ¹⁰Bristol Myers Squibb, Princeton
Background/Purpose: PsA affects male and female patients equally; however, variations in manifestations and treatment response exist between sexes. Deucravacitinib is an oral, selective, allosteric tyrosine…
Abstract Number: 0475 • ACR Convergence 2025
Drug Discontinuation in Inflammatory Arthritis Following Mandatory Non-Medical Switching from Originator to Biosimilar in Quebec, Canada
Cristiano Moura¹, Luck Lukusa², Denis Choquette³, Gilles Boire⁴, Nathalie Carrier⁵, Autumn Neville² and Sasha Bernatsky⁶, ¹Research Institute of the McGill University Health Center, Montréal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, Canada, ³Institut de Rhumatologie de Montréal, Saint-Donat-de-Montcalm, Canada, ⁴Retired, Sherbrooke, QC, Canada, ⁵Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: In April 2022, the Canadian province of Quebec introduced a mandatory non-medical switch to biosimilars for persons on bio-originators to manage healthcare costs. Our…
Abstract Number: 0581 • ACR Convergence 2025
Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
Philip J. Mease¹, Álvaro González Cantero², Jennifer Soung³, April Armstrong⁴, Joseph F Merola⁵, Fabian Proft⁶, Laure Gossec⁷, Dafna D. Gladman⁸, Laura Coates⁹, Lichen Teng¹⁰, Jimena Vázquez¹¹, Cynthia Deignan¹² and Arthur Kavanaugh¹³, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Dermatology, Ramón y Cajal University Hospital, Madrid, Spain, ³Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁴University of California Los Angeles, Los Angeles, ⁵Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁶Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Sorbonne Université, Pitié Salpêtrière Hospital, Paris, France, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ¹⁰Amgen Inc., Thousand Oaks, ¹¹Amgen Inc., Thousand Oaks, CA, ¹²Amgen, Inc., Agoura Hills, CA, ¹³University of California, San Diego, School of Medicine, San Diego, CA
Background/Purpose: The prevalence of cardiometabolic diseases, including obesity and diabetes, is higher in patients with psoriatic arthritis (PsA) than those without PsA.1,2 Metabolic syndrome is…
Abstract Number: 2687 • ACR Convergence 2025
Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts
Lihi Eder¹, Uma Scher², Kyra Chen³, Alexandra L. Rice³, Sydney Thib⁴ and Rebecca Haberman⁵, ¹University of Toronto, Toronto, ON, Canada, ²NYU School of Medicine, Scarsdale, NY, ³NYU Grossman School of Medicine and NYU Langone Health Psoriatic Arthritis Center, New York, ⁴Women's College Research Institute, Women's College Hospital, Toronto, Canada, ⁵NYU Langone Health, New York, NY
Background/Purpose: Obesity is highly prevalent in psoriatic arthritis (PsA) and is associated with reduced therapeutic response, worse disease outcomes, and increased cardiometabolic risk. Glucagon-like peptide-1…
Abstract Number: 2364 • ACR Convergence 2025
Real-World Characteristics and Treatment Patterns of Difficult-to-Treat Psoriatic Arthritis
Milad Heydari-Kamjani¹, Jennifer Murphy² and Marina Magrey³, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University Hospitals, Cleveland Medical Center, cleveland, OH, ³Case Western Reserve University School of Medicine/University Hospitals Cleveland, Richfield, OH
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease with variable clinical presentation and treatment response. A subset of PsA patients are difficult to treat…
Abstract Number: 2325 • ACR Convergence 2025
Association of Galectin-3 and Myocardial Dysfunction in Patients with Psoriatic Arthritis
Natalia Guajardo-Jauregui¹, Iris J. Colunga-Pedraza², Dionicio A. Galarza-Delgado², Jose R Azpiri-Lopez³, Jesus Alberto Cardenas-de la Garza⁴, Diana E. Flores-Alvarado⁵ and Rosa Arvizu-Rivera⁶, ¹Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁵Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Nuevo Leon, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico
Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated condition associated with an increased risk of cardiovascular (CV) events due to disease-specific characteristics. Galectin-3 (Gal-3) is a…
Abstract Number: 1959 • ACR Convergence 2025
The development and validation of a Diagnostic Ultrasound Enthesitis Score (DUET) for Psoriatic Arthritis
Lihi Eder¹, Ricardo Acayaba de Toledo², Catherine Bakewell³, Philippe Carron⁴, Basant Elnady⁵, Amir Haddad⁶, Arthur Kavanaugh⁷, Fahmeen J. Afgani⁸, Arnon Katz⁹, Minna Kohler¹⁰, josefina marin¹¹, Nam Nguyen¹², Adrien NZEUSSEU TOUKAP¹³, Ari Polachek¹⁴, Ernesto Rodriguez¹⁵, Marcos Rosemffet¹⁶, Abha Singh¹⁷, Maria S. Stoenoiu¹⁸, Agnes Szentpetery¹⁹, Iliara Tinazzi²⁰, Janeth Yinh²¹, Mu Yang²², Richard Cook²², Gurjit Kaeley²³ and Sibel Aydin²⁴, ¹University of Toronto, Toronto, ON, Canada, ²Centro Integrado de Pesquisas (CIP) do Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil, ³Intermountain Healthcare Medical Group, Salt Lake City, ⁴Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵Research Centre at Al Hada Armed Forces Hospital, Cairo, Egypt, ⁶Carmel Medical Center, Haifa, Israel, ⁷University of California, San Diego, School of Medicine, San Diego, CA, ⁸Women's College Hospital, Toronto, Canada, ⁹GRAPPA, Seattle, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹¹Hospital Universitario Rey Juan Carlos, Madrid, Spain, ¹²University of Toronto, Toronto, Canada, ¹³Cliniques Universitaires Saint-Luc, St.-Lambrechts-Woluwe, Belgium, ¹⁴Rheumatology Institute of Beilinson Hospital, Petah Tikva, Israel, ¹⁵Florida Medical Clinic, Tampa, ¹⁶Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ¹⁷Altman Clinical and Translational Research Institute, University of California San Diego, San Diego, CA, ¹⁸Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁹Uppsala University Hospital, Djursholm, Sweden, ²⁰Ospedale Sacro Cuore-Don Calabria, Verona, Italy, ²¹Massachusetts General Hospital, Boston, MA, ²²University of Waterloo, Waterloo, Canada, ²³UF COM-J, Ponte Vedra Beach, FL, ²⁴Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Enthesitis is a key lesion in psoriatic arthritis (PsA). The Diagnostic Ultrasound Enthesitis Tool (DUET) study aimed to develop and validate a novel sonographic…
Abstract Number: 1462 • ACR Convergence 2025
Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Kim Hoyt⁹, Weibin Bao¹⁰ and Karl Gaffney¹¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹¹Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Secukinumab has demonstrated long-lasting efficacy and a favorable safety profile across multiple clinical trials and domains of psoriatic disease. Real-world data provides additional valuable…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].